A 52-year-old man of Indian descent presents with a 6-month history of fatigue and polyuria. He is overweight (BMI 28 kg/m²) with acanthosis nigricans on the neck and axillae. Fasting blood glucose is 156 mg/dL, and HbA₁c is 8.2%. C-peptide is 2.8 ng/mL (normal 0.8–3.1). Anti-GAD and anti-islet cell antibodies are negative. Blood pressure is 138/88 mmHg, and lipid panel shows triglycerides 240 mg/dL with low HDL cholesterol. What is the most appropriate first-line pharmacological intervention?

Explanation

## Diagnosis and Management: Type 2 Diabetes Mellitus ### Clinical Diagnosis **Key Point:** This patient has Type 2 diabetes, confirmed by: - **Insulin resistance markers**: obesity (BMI 28), acanthosis nigricans, dyslipidemia (elevated triglycerides, low HDL) - **Preserved β-cell function**: C-peptide 2.8 ng/mL (normal range) - **Negative autoimmune serology**: rules out Type 1 or LADA - **Insidious onset** in a middle-aged, overweight individual **High-Yield:** Acanthosis nigricans is a clinical sign of severe insulin resistance and is strongly associated with Type 2 DM and metabolic syndrome. ### Why Metformin Is First-Line | Feature | Metformin | Sulfonylurea | Pioglitazone | Insulin | |---------|-----------|--------------|--------------|----------| | **Mechanism** | ↓ hepatic glucose production, ↑ insulin sensitivity | ↑ insulin secretion | ↑ insulin sensitivity | Exogenous insulin replacement | | **Weight effect** | Neutral/weight loss | Weight gain | Weight gain | Weight gain | | **Hypoglycemia risk** | None (monotherapy) | High | Low | High | | **CV benefit** | Yes (UKPDS) | Neutral/harmful | Neutral | Neutral | | **Renal protection** | Yes | No | Yes | Yes | | **First-line status** | **Yes** | No | No | Reserved for advanced disease | **Clinical Pearl:** Metformin is the **gold standard first-line agent** for Type 2 DM according to ADA, EASD, and Indian Diabetes Association guidelines. It addresses the primary pathophysiology (hepatic insulin resistance and impaired glucose uptake), does not cause weight gain, and has cardiovascular and renal protective effects. ### Lifestyle Modification Is Essential **Mnemonic: DIET** - **D**ietary modification (low glycemic index, reduced refined carbohydrates) - **I**ncreased physical activity (150 min/week moderate intensity) - **E**nergy deficit (5–10% weight loss improves insulin sensitivity) - **T**herapeutic drug (metformin as pharmacotherapy adjunct) Lifestyle intervention alone can reduce progression to diabetes by ~58% in prediabetic individuals (Diabetes Prevention Program). In newly diagnosed Type 2 DM with modest hyperglycemia (HbA₁c 8.2%), metformin + lifestyle modification is often sufficient. ### Why Not the Other Options? **Insulin glargine:** Reserved for advanced Type 2 DM (HbA₁c >10% despite dual therapy) or acute decompensation. Starting insulin in a patient with preserved C-peptide and HbA₁c 8.2% is premature and increases hypoglycemia risk and weight gain. **Sulfonylurea (gliclazide):** Although effective at lowering glucose, sulfonylureas cause: - Weight gain (average 2–3 kg) - Hypoglycemia (especially in elderly or renal impairment) - No cardiovascular or renal benefit - Increased risk of β-cell exhaustion over time Sulfonylureas are second-line agents, reserved for patients who fail metformin or require rapid glucose lowering. **Pioglitazone monotherapy:** Thiazolidinediones improve insulin sensitivity but cause weight gain, fluid retention, and increased fracture risk in women. They are not recommended as monotherapy for initial treatment. ### Comorbidity Management **High-Yield:** This patient also has: - **Hypertension** (BP 138/88): target <130/80 mmHg in diabetes; consider ACE inhibitor or ARB for renal protection - **Dyslipidemia**: elevated triglycerides and low HDL warrant statin therapy (atorvastatin 40 mg daily) per ATP III guidelines **Clinical Pearl:** Metformin may modestly reduce triglycerides and improve lipid profile, providing additional benefit in this metabolically dyslipidemic patient. [cite:Harrison 21e Ch 397; ADA Standards of Care 2024]